Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Lymphoma
  Free Subscription

Articles published in
Br J Haematol
    September 2025
  1. OLSZEWSKI AJ, Treaba DO, Winter A, Donnelly S, et al
    Loncastuximab tesirine elicits complete responses in secondary central nervous system lymphoma.
    Br J Haematol. 2025 Sep 21. doi: 10.1111/bjh.70178.
    >> Share

  2. PATZKE S, Cascione L, Melhus KB, Munz N, et al
    Comprehensive analysis of (177)Lu-lilotomab satetraxetan in lymphoma cell lines: Implications for precision radioimmunotherapy and combination schemes.
    Br J Haematol. 2025 Sep 18. doi: 10.1111/bjh.70143.
    >> Share

  3. LI Y, Jin L, Liu W, Liu Y, et al
    Clinical features, mutational landscape and their prognostic impact in Chinese paediatric patients with T-cell lymphoblastic lymphoma.
    Br J Haematol. 2025 Sep 16. doi: 10.1111/bjh.70097.
    >> Share

  4. BAHABRI AS, Lau C, Kim VHD, Alexander S, et al
    Incidence and impact of prior history of serious infection in paediatric lymphoma: A population-based study.
    Br J Haematol. 2025 Sep 15. doi: 10.1111/bjh.70157.
    >> Share

  5. KUHNL A, Bouziana S, Barrington SF, Galani S, et al
    MTV-guided radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T-cell therapy.
    Br J Haematol. 2025 Sep 11. doi: 10.1111/bjh.70137.
    >> Share

  6. VODICKA P, Hamova I, Velasova A, Kupcova K, et al
    Circulating tumour DNA as a predictor of survival of patients with diffuse large B-cell lymphoma in a daily practice.
    Br J Haematol. 2025 Sep 7. doi: 10.1111/bjh.70128.
    >> Share

  7. CHAGANTI S, Dulobdas V, Wilson MR, Tucker D, et al
    Clinical management of bispecific antibody therapy for lymphoma: A British Society for Haematology Good Practice Paper.
    Br J Haematol. 2025 Sep 5. doi: 10.1111/bjh.70018.
    >> Share

  8. SONG Y, Zou D, Yang H, Wu J, et al
    Two-year follow-up of relmacabtagene autoleucel in relapsed or refractory follicular lymphoma in RELIANCE study.
    Br J Haematol. 2025 Sep 1. doi: 10.1111/bjh.20122.
    >> Share

  9. NORDKIN M, Fadaos N, Leiba R, Sharon-Horesh N, et al
    Duration of anti-CD20 monoclonal antibody maintenance positively correlates with clinical outcomes in follicular lymphoma patients, supporting adherence to the recommended 2-year maintenance paradigm.
    Br J Haematol. 2025;207:1104-1107.
    >> Share

  10. BARONE A, De Philippis C, Stella F, Dodero A, et al
    Allogeneic transplantation after failure of chimeric antigen receptor-T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes.
    Br J Haematol. 2025;207:956-964.
    >> Share

  11. JO T, Arai Y, Shimizu T, Kitawaki T, et al
    Consistent ex vivo cell proliferation during manufacturing predicts favourable outcomes post-CAR-T-cell therapy.
    Br J Haematol. 2025;207:1002-1010.
    >> Share

  12. JOHNSTONE P, Higgins M, Prince HM, Lade S, et al
    Large-cell transformation of mycosis fungoides: Patterns of care and patient outcomes.
    Br J Haematol. 2025;207:824-833.
    >> Share

    August 2025
  13. MARIOTTI J, Pinton C, Giordano L, Taurino D, et al
    Reduced incidence of relapse after checkpoint inhibitors relative to brentuximab vedotin as salvage therapy before allogeneic stem cell transplantation for refractory/relapsed Hodgkin lymphoma: A retrospective analysis.
    Br J Haematol. 2025 Aug 31. doi: 10.1111/bjh.70091.
    >> Share

  14. KLEINSTERN G, Robinson DP, Abu Seir R, Perlman R, et al
    European-based polygenic risk score and genome-wide association study of B-cell non-Hodgkin lymphoma subtypes in Israeli Jews and Palestinian Arabs.
    Br J Haematol. 2025 Aug 31. doi: 10.1111/bjh.70125.
    >> Share

  15. LUMINARI S, Barbieri E, Nizzoli ME
    Towards a chemo-free approach for follicular lymphoma.
    Br J Haematol. 2025 Aug 30. doi: 10.1111/bjh.70126.
    >> Share

  16. YU F, Yu X, Hu X, Jiang E, et al
    Comprehensive risk stratification for adult T-cell lymphoblastic lymphoma undergoing allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2025 Aug 26. doi: 10.1111/bjh.70102.
    >> Share

  17. KOCA O, Eskazan AE
    Refining the risk stratification in advanced-stage classical Hodgkin lymphoma: A critical analysis of clinical prediction models.
    Br J Haematol. 2025 Aug 22. doi: 10.1111/bjh.70115.
    >> Share

  18. TE VRUGT M, Newman H, Teachey DT, Burkhardt B, et al
    T-cell lymphoblastic lymphoma in children, adolescents and young adults.
    Br J Haematol. 2025 Aug 13. doi: 10.1111/bjh.70053.
    >> Share

  19. MORIMOTO S, Jo T, Kitawaki T, Sakamoto T, et al
    Prolonged chimeric antigen receptor-T apheresis to infusion time is associated with inferior outcomes in diffuse large B-cell lymphoma.
    Br J Haematol. 2025 Aug 11. doi: 10.1111/bjh.70090.
    >> Share

  20. TRAB T, Ranadottir T, Chanchiri I, Ludvigsen Al-Mashhadi A, et al
    Secondary central nervous system lymphoma (SCNSL) in mantle cell lymphoma (MCL): Characteristics and risk factors in a Danish nationwide population-based study.
    Br J Haematol. 2025 Aug 8. doi: 10.1111/bjh.70082.
    >> Share

    July 2025
  21. CARPIO C, de la Cruz-Vicente F, Garcia-Sanz R, Zeberio I, et al
    A phase Ib/II trial combining brentuximab vedotin with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for older patients with untreated classical Hodgkin lymphoma: A multicentre GELTAMO trial.
    Br J Haematol. 2025 Jul 25. doi: 10.1111/bjh.70028.
    >> Share

  22. HOSSAIN NM, Ahn KW, Patel J, Lian Q, et al
    Chimeric antigen receptor T-cell therapy for high-grade B-cell lymphoma NOS.
    Br J Haematol. 2025 Jul 22. doi: 10.1111/bjh.70020.
    >> Share

  23. REGAZZO G, Vari G, Marchesi F, Diaz Mendez AB, et al
    A predictive serum miRNA signature impacts diffuse large B-cell lymphoma cell viability via inhibition of EGLN1 and TXNRD1 regulators of ferroptosis.
    Br J Haematol. 2025 Jul 20. doi: 10.1111/bjh.70017.
    >> Share

  24. KHAVANDI MM, Strati P, Habibollahi P
    Minimally invasive percutaneous lymphangiography and embolisation for spontaneous chyle leaks in patients with lymphoma.
    Br J Haematol. 2025 Jul 15. doi: 10.1111/bjh.70007.
    >> Share

  25. SEVERINSEN FT, Simonsen MR, Futtrup Maksten E, Jakobsen LH, et al
    Late infections after high-dose therapy and autologous stem cell transplantation for lymphoma: A Danish population-based study.
    Br J Haematol. 2025 Jul 13. doi: 10.1111/bjh.20262.
    >> Share

  26. PARTANEN A, Ronka A, Anttalainen A, Ukkola-Vuoti L, et al
    Nodal peripheral T-cell lymphoma in Finland between 2007 and 2019: Incidence, late morbidity and survival.
    Br J Haematol. 2025 Jul 10. doi: 10.1111/bjh.20253.
    >> Share

  27. MOIOLI A, Visco C
    We are on the right track for mantle cell lymphoma.
    Br J Haematol. 2025 Jul 6. doi: 10.1111/bjh.20259.
    >> Share

  28. ALZAHRANI M, Gerrie AS, Sehn LH, Scott DW, et al
    Therapeutic advances and gradual improvement in overall survival in mantle cell lymphoma over four decades.
    Br J Haematol. 2025 Jul 2. doi: 10.1111/bjh.20239.
    >> Share

  29. GASCON P, Frankel D, Fritz S, Comet A, et al
    Vitrectomy as a rapid diagnostic tool for lymphoma: Cytology and flow cytometry approach.
    Br J Haematol. 2025 Jul 1. doi: 10.1111/bjh.20250.
    >> Share

  30. CASSANELLO G, Luttwak E, Brown S, Devlin SM, et al
    Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experience.
    Br J Haematol. 2025 Jul 1. doi: 10.1111/bjh.20234.
    >> Share

  31. HANAJIRI R, Wakabayashi H, Ishigiwa K, Ohara F, et al
    Robust CAR T-cell expansion and superior outcomes in DLBCL patients in complete response at infusion.
    Br J Haematol. 2025;207:180-188.
    >> Share

    June 2025
  32. SHARP J, Zhao Q, Voorhees TJ, Bond DA, et al
    Acute kidney injury after chimeric antigen receptor T-cell therapy is associated with inferior survival in patients with relapsed/refractory large B-cell lymphoma.
    Br J Haematol. 2025 Jun 30. doi: 10.1111/bjh.20240.
    >> Share

  33. MOLINA F, Sureda A, Mussetti A
    Allogeneic haematopoietic cell transplant should still be considered as a curative option for relapsed/refractory large B-cell lymphoma, including in the CAR T-cell era.
    Br J Haematol. 2025 Jun 25. doi: 10.1111/bjh.20217.
    >> Share

  34. WEI C, Zhang Y, Zhao D, Zhang W, et al
    Germline defects of familial haemophagocytic lymphohistiocytosis-Related genes may represent a predisposing factor for mature T- and natural killer-cell lymphoma.
    Br J Haematol. 2025 Jun 23. doi: 10.1111/bjh.20231.
    >> Share

  35. UPPAL M, Joseph A, Drill E, Hamlin P, et al
    Predictors of outcomes with covalent BTK inhibitor treatment in relapsed/refractory TP53-mutant mantle cell lymphoma.
    Br J Haematol. 2025 Jun 23. doi: 10.1111/bjh.20202.
    >> Share


  36. Correction to "Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma".
    Br J Haematol. 2025 Jun 19. doi: 10.1111/bjh.20237.
    >> Share

  37. CHUNG K, Ng LS, Yee CI, Bansal R, et al
    Impact of granulocyte colony-stimulating factor on safety of chimeric antigen receptor-T-cell therapy in non-Hodgkin lymphoma.
    Br J Haematol. 2025 Jun 17. doi: 10.1111/bjh.20207.
    >> Share

  38. YILMAZ U, Terzi Demirsoy E, Keklik Karadag F, Hatipoglu U, et al
    Simplified Molecular International Prognostic Index as an eligibility criterion for clinical trials: Analysis of the Turkish Lymphoma Study Group's large B-cell lymphoma cohort.
    Br J Haematol. 2025 Jun 16. doi: 10.1111/bjh.20111.
    >> Share

  39. HUIYING Z, Congwei J, Yue C, Lu Z, et al
    Arborising telangiectasia in intravascular large B-cell lymphoma.
    Br J Haematol. 2025 Jun 12. doi: 10.1111/bjh.20172.
    >> Share

  40. CHIRIAC R, Baseggio L
    Chronic lymphocytic leukaemia extravaganza: Vacuolated lymphoma cells.
    Br J Haematol. 2025 Jun 11. doi: 10.1111/bjh.20162.
    >> Share

  41. NOVO M, Frascione PMM, Castellino A, Marcheselli L, et al
    Copanlisib in combination with rituximab and bendamustine for transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma patients: Results from the phase II multicentre FIL Copa-BR trial from Fondazione Italiana Linfomi (FIL).
    Br J Haematol. 2025 Jun 10. doi: 10.1111/bjh.20204.
    >> Share

  42. DITTUS C, Weinstock MJ, Barnes J, Sandoval-Sus J, et al
    Final results of a multicentre pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide and prednisone (BV-CHEP) for the treatment of aggressive adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2025 Jun 3. doi: 10.1111/bjh.20177.
    >> Share

  43. SORIAL MN, Han JX, Koh MJ, Boussi L, et al
    Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: A global PETAL Consortium study.
    Br J Haematol. 2025;206:1664-1677.
    >> Share

    May 2025
  44. GLEESON M, Gonzalez Arias C, Cunningham D, Peckitt C, et al
    The role of PET/CT in peripheral T-cell lymphoma: Results from the PET/CT substudy of the UK NCRI phase 2 CHEMO-T trial.
    Br J Haematol. 2025 May 26. doi: 10.1111/bjh.20160.
    >> Share

  45. HARLAY V, Gallardo C, Beaufils N, Astier A, et al
    Evaluation of MYD88 p.L265P detection by digital droplet polymerase chain reaction in cerebrospinal fluid for integrated diagnosis of primary large B-cell lymphoma of the central nervous system.
    Br J Haematol. 2025 May 25. doi: 10.1111/bjh.20167.
    >> Share

  46. SRINIVASAN S, Narayan A, Dhamne C, Chichra A, et al
    Combination of fixed low-dose nivolumab and bendamustine in children with high-risk relapsed/refractory classical Hodgkin lymphoma.
    Br J Haematol. 2025 May 20. doi: 10.1111/bjh.20148.
    >> Share

  47. CHAGANTI S, Fox CP, Maybury BD, Burton C, et al
    Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology Guideline.
    Br J Haematol. 2025 May 19. doi: 10.1111/bjh.20129.
    >> Share

  48. HAUJIR A, Tostesen M, El-Galaly TC, Larsen TS, et al
    Effectiveness of rituximab and biosimilar rituximab in untreated diffuse large B-cell lymphoma, a Danish population-based analysis.
    Br J Haematol. 2025 May 15. doi: 10.1111/bjh.20155.
    >> Share

  49. HAFI M, Iyengar S, Wotherspoon A, Cunningham D, et al
    Involvement of the gastrointestinal tract by mantle cell lymphoma.
    Br J Haematol. 2025 May 15. doi: 10.1111/bjh.20048.
    >> Share

  50. LOWE EJ, Woessmann W
    Anaplastic large cell lymphoma in children and adolescents.
    Br J Haematol. 2025 May 12. doi: 10.1111/bjh.20154.
    >> Share

  51. TANG C, Downie C, Sagoo MS, Pringle E, et al
    An international real-world study of primary vitreoretinal lymphoma from the Australasian lymphoma alliance and collaborators.
    Br J Haematol. 2025 May 6. doi: 10.1111/bjh.20115.
    >> Share

  52. AOKI T, Salib M, Suleman A, Ghanem N, et al
    Distinct characteristics and social determinants in adult T-cell leukaemia/lymphoma patients at a tertiary cancer centre in Canada.
    Br J Haematol. 2025 May 6. doi: 10.1111/bjh.20132.
    >> Share

  53. HARROP S, Casan J, Rose H, Sullivan M, et al
    Heterozygous germline TET2 loss-of-function variants associated with an ALPS-like phenotype.
    Br J Haematol. 2025;206:1330-1334.
    >> Share

    April 2025
  54. VALLET N, Picou F, Arbion F, Doyen H, et al
    Aberrant antioxidant responses in B-cell non-Hodgkin lymphoma.
    Br J Haematol. 2025 Apr 30. doi: 10.1111/bjh.20108.
    >> Share

  55. HERBAUX C, Bachy E, Bouabdallah R, Guidez S, et al
    Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group.
    Br J Haematol. 2025 Apr 26. doi: 10.1111/bjh.20109.
    >> Share

  56. HARRYSSON S, Eloranta S, Antonilli S, Runason Simonsen M, et al
    Temporal trends in relative survival of diffuse large B-cell lymphoma in Sweden and Denmark in the era of targeted and cellular therapies.
    Br J Haematol. 2025 Apr 23. doi: 10.1111/bjh.20104.
    >> Share

  57. SUZUKI T, Fujii K, Matsunaga N, Sasaki H, et al
    Impact of MYD88 and/or CD79B mutations on central nervous system relapse in patients with diffuse large B-cell lymphoma.
    Br J Haematol. 2025 Apr 22. doi: 10.1111/bjh.20099.
    >> Share

  58. NIRMAL G, Thankamony P, Nair RA, Nair M, et al
    Resource-adapted strategies in the management of paediatric Burkitt lymphoma in low- and middle-income country setting and outcomes: An Indian centre experience.
    Br J Haematol. 2025 Apr 22. doi: 10.1111/bjh.20093.
    >> Share

  59. CERIANI L, Milan L, Chauvie S, Zucca E, et al
    Understandings 18 FDG PET radiomics and its application to lymphoma.
    Br J Haematol. 2025 Apr 15. doi: 10.1111/bjh.20074.
    >> Share

  60. MIAO Y, Qian S, Gao L, Zhou Z, et al
    Prognostic impacts of RHOA G17V mutation in cell-free DNA assessed by droplet digital polymerase chain reaction in patients with angioimmunoblastic T-cell lymphoma.
    Br J Haematol. 2025 Apr 7. doi: 10.1111/bjh.20071.
    >> Share

  61. LOPEDOTE P, Shouse G, Puverel S, Muir A, et al
    A chemotherapy-free regimen of acalabrutinib, umbralisib and ublituximab achieved high response rates and undetectable minimal residual disease in patients with untreated mantle cell lymphoma.
    Br J Haematol. 2025 Apr 2. doi: 10.1111/bjh.20041.
    >> Share

  62. GIORDANO C, Picardi M, Pugliese N, Vincenzi A, et al
    Bendamustine supercharge plus brentuximab vedotin as early salvage therapy following failure to obtain complete metabolic remission after two cycles of adriamycin-bleomycin-vinblastine-dacarbazine for classic Hodgkin lymphoma in patients aged
    Br J Haematol. 2025 Apr 2. doi: 10.1111/bjh.20053.
    >> Share

    March 2025
  63. PIEROG O, Craig T, Jennings J, Borowitz MJ, et al
    The real-world application of T-cell receptor constant beta-1 chain antibody assay in cutaneous T-cell lymphoma.
    Br J Haematol. 2025 Mar 24. doi: 10.1111/bjh.20060.
    >> Share

  64. BRAY JS, Thomas GR, Smith VM, Wright A, et al
    In vitro comparison of CD20xCD3 biosimilar antibodies against diffuse large B-cell lymphoma (DLBCL) cell lines with different levels of expression of CD20.
    Br J Haematol. 2025 Mar 3. doi: 10.1111/bjh.20033.
    >> Share

  65. MOZAS P, Ould Ammar R, Chartier L, Nastoupil L, et al
    A low lymphocyte-to-monocyte ratio is independently associated with early relapse (POD24) in high tumour burden follicular lymphoma: A RELEVANCE subanalysis.
    Br J Haematol. 2025 Mar 3. doi: 10.1111/bjh.20038.
    >> Share

  66. MALLET V, Torres HA
    Hepatitis E virus infection after CAR T-cell treatment: An important complication in patients already facing significant health challenges.
    Br J Haematol. 2025;206:1020-1021.
    >> Share

    February 2025
  67. MATO S, Carita L, Colmenero A, Andres M, et al
    Comprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents.
    Br J Haematol. 2025 Feb 26. doi: 10.1111/bjh.20012.
    >> Share

  68. ZHAO J, Liu TF, Wu KF, Yang LC, et al
    Clinical and molecular characteristics of paediatric mature B-cell acute lymphocytic leukaemia and non-Hodgkin lymphoma with bone marrow involvement: A joint study between the CCCG leukaemia and lymphoma groups.
    Br J Haematol. 2025 Feb 17. doi: 10.1111/bjh.20011.
    >> Share

  69. WANG G, Wang F
    Immunoglobulin inclusions were released from lymphoma cells and deposited as cryoglobulin crystals in a peripheral blood film.
    Br J Haematol. 2025 Feb 17. doi: 10.1111/bjh.20005.
    >> Share

  70. KOH YK, Yoon SH, Kang SH, Koh KN, et al
    Immunosuppressive therapy as first-line and relapse treatment in paediatric subcutaneous panniculitis-like T-cell lymphoma.
    Br J Haematol. 2025 Feb 16. doi: 10.1111/bjh.20014.
    >> Share

  71. IVANOVA VS, Menter T, Cui N, Leary P, et al
    Distinct subtypes of post-transplant lymphoproliferative disorders: CHIP-like mutations in early lesions and substantial mutational differences between EBV-positive and EBV-negative diffuse large B-cell lymphomas.
    Br J Haematol. 2025;206:484-504.
    >> Share

  72. EL-GALALY TC, Roug AS, Kristensen DT
    A successful clinical trial ecosystem offers equal opportunities for all citizens.
    Br J Haematol. 2025;206:788-789.
    >> Share

    January 2025
  73. DRAGOI D, Cusworth S, Oldham L, Sanderson R, et al
    CAR T access and outcomes in large B-cell lymphoma according to ethnicity and socioeconomic deprivation in the UK.
    Br J Haematol. 2025 Jan 16. doi: 10.1111/bjh.19997.
    >> Share

  74. SHIWAKU T, Tamefusa K, Ishida H, Fujiwara K, et al
    Paediatric anaplastic large-cell lymphoma with cardiac tamponade.
    Br J Haematol. 2025 Jan 12. doi: 10.1111/bjh.19980.
    >> Share

  75. CHIRIAC R
    Concomitant HIV-associated plasmablastic lymphoma and visceral leishmaniasis at initial presentation.
    Br J Haematol. 2025 Jan 12. doi: 10.1111/bjh.19971.
    >> Share

  76. MUNAKATA W, Kumode T, Goto H, Fukuhara N, et al
    A phase II study of zandelisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma: ME-401-K02 study.
    Br J Haematol. 2025 Jan 8. doi: 10.1111/bjh.19994.
    >> Share

  77. LEW-DERIVRY L, Chevillon F, Brice P, Bigenwald C, et al
    Should adolescents and young adults with Hodgkin lymphoma be treated as children or adults?
    Br J Haematol. 2025 Jan 5. doi: 10.1111/bjh.19985.
    >> Share

  78. LIN J, Mu Y, Liu L, Meng Y, et al
    Machine learning based on multiplatform tests assists in subtype classification of mature B-cell neoplasms.
    Br J Haematol. 2025;206:224-234.
    >> Share

  79. CAPES A, Morin A, Banet A, Suner L, et al
    Severe cytopenia after chimeric antigen receptor-T cell driven by large granular lymphocytes and responsive to steroids.
    Br J Haematol. 2025;206:180-185.
    >> Share

    December 2024
  80. STELLA F, Chiappella A, Magni M, Bonifazi F, et al
    Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study.
    Br J Haematol. 2024 Dec 22. doi: 10.1111/bjh.19961.
    >> Share

  81. ZAMMAR G, Cheah CY
    Treating asymptomatic follicular lymphoma: What is the score?
    Br J Haematol. 2024 Dec 18. doi: 10.1111/bjh.19949.
    >> Share

  82. DE LA IGLESIA-SAN SEBASTIAN I, Lopez-Esteban M, Bastos-Oreiro M, Fernandez de Cordoba-Onate S, et al
    Chimeric antigen receptor copies in cell-free DNA predict relapse in aggressive B-cell lymphoma patients treated with CAR T-cell therapy.
    Br J Haematol. 2024 Dec 12. doi: 10.1111/bjh.19916.
    >> Share

  83. STRATI P, Agajanian R, Lossos IS, Coleman M, et al
    Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003).
    Br J Haematol. 2024 Dec 12. doi: 10.1111/bjh.19951.
    >> Share

  84. CHOY J, Lewis KL
    In the SARS-CoV-2 era, do we need to be afraid of obinutuzumab?
    Br J Haematol. 2024;205:2113-2115.
    >> Share

  85. CALIMERI T, Ferreri AJM
    CNS prophylaxis in large B-cell lymphomas: A balance with three pans.
    Br J Haematol. 2024;205:2116-2118.
    >> Share

    November 2024
  86. MARZOLINI MAV, Qian W, Clifton-Hadley L, Patrick P, et al
    Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful-waiting.
    Br J Haematol. 2024 Nov 27. doi: 10.1111/bjh.19918.
    >> Share

  87. JONES DA, Spencer K, Ramroth J, Probert J, et al
    Inequalities in geographic barriers and patient representation in lymphoma clinical trials across England.
    Br J Haematol. 2024 Nov 27. doi: 10.1111/bjh.19907.
    >> Share

  88. SCHENA A, Quaglia FM, Parisi A, Ferrarini I, et al
    Pembrolizumab as salvage treatment for T-cell/histiocyte-rich and Epstein-Barr virus-positive large B-cell lymphoma.
    Br J Haematol. 2024 Nov 13. doi: 10.1111/bjh.19883.
    >> Share

  89. SCHWARZ M, Mozayani B, Trauner M, Stattermayer AF, et al
    Chronic hepatitis E in a patient after chimeric antigen receptor-T-cell treatment for diffuse large B-cell lymphoma and rapid progression towards decompensated liver cirrhosis.
    Br J Haematol. 2024 Nov 7. doi: 10.1111/bjh.19892.
    >> Share

  90. KIM JL, Villa D, Tonseth RP, Gerrie AS, et al
    Long-term follow-up of bulky classic Hodgkin lymphoma managed with ABVD and PET-guided RT demonstrates excellent outcomes in PET-negative cases.
    Br J Haematol. 2024 Nov 7. doi: 10.1111/bjh.19859.
    >> Share

  91. BARRETT A, Shah N, Chadwick A, Burns D, et al
    Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical Hodgkin lymphoma: A British Society for Haematology Good Practice Paper.
    Br J Haematol. 2024 Nov 6. doi: 10.1111/bjh.19840.
    >> Share

  92. LI JR, Shaw VR, Parthasarathy A, Li Y, et al
    Prognostic stratification in DLBCL patients with aberrant MYC gene.
    Br J Haematol. 2024;205:1782-1793.
    >> Share

  93. CAMPBELL BA, Dobos G, Haider Z, Bagot M, et al
    Improving disease-specific survival for patients with Sezary syndrome in the modern era of systemic therapies.
    Br J Haematol. 2024;205:1825-1829.
    >> Share

    October 2024
  94. KARSTEN IE, Shumilov E, Schmitz N, Lenz G, et al
    Sequencing of therapy for patients with diffuse large B-cell lymphoma in the era of novel drugs.
    Br J Haematol. 2024 Oct 28. doi: 10.1111/bjh.19860.
    >> Share

  95. FUKUOKA K, Zhao J, Oshima K, Honda M, et al
    Isolated testicular second-relapsed T-lymphoblastic lymphoma after allogeneic stem cell transplantation: Therapeutic implication from sequential molecular genetic analysis.
    Br J Haematol. 2024 Oct 27. doi: 10.1111/bjh.19870.
    >> Share

  96. ALBANO D
    (18)F-FDG PET/CT impact in grade 3B follicular lymphoma.
    Br J Haematol. 2024 Oct 27. doi: 10.1111/bjh.19852.
    >> Share

  97. JIANG L, Dreyling M, Hermine O, Mansmann U, et al
    Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL Network.
    Br J Haematol. 2024 Oct 23. doi: 10.1111/bjh.19854.
    >> Share

  98. YOSHIMITSU M, Tanaka T, Nakano N, Kato K, et al
    Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post-transplantation cyclophosphamide for adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2024 Oct 19. doi: 10.1111/bjh.19835.
    >> Share

  99. BUCCHERI V, Moreira FR, Biasoli I, Castro N, et al
    External validation and calibration of the HoLISTIC Consortium's advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI) in the Brazilian Hodgkin lymphoma registry.
    Br J Haematol. 2024 Oct 17. doi: 10.1111/bjh.19824.
    >> Share

  100. LE GALLO M, Rose J, Safa F, Cottin L, et al
    Bone marrow metastasis of rhabdomyosarcoma mimicking high-grade lymphoma in a young man.
    Br J Haematol. 2024 Oct 15. doi: 10.1111/bjh.19795.
    >> Share

  101. CHIRIAC R, Baseggio L
    Monomorphic epitheliotropic intestinal T-cell lymphoma involving the aqueous humour.
    Br J Haematol. 2024 Oct 14. doi: 10.1111/bjh.19806.
    >> Share

  102. BARRACLOUGH A, Lee ST, Villa D, Hapgood G, et al
    The value of semiquantitative PET features and end-of-therapy PET in grade 3B follicular lymphoma.
    Br J Haematol. 2024 Oct 13. doi: 10.1111/bjh.19823.
    >> Share

  103. SHERIF M, Schafer H, Scharf S, van Oostendorp V, et al
    EZB-type diffuse large B-cell lymphoma cell lines have superior migration capabilities compared to MCD-type.
    Br J Haematol. 2024 Oct 2. doi: 10.1111/bjh.19778.
    >> Share

  104. WU S, Luo Q, Li F, Zhang S, et al
    Development of novel humanized CD19/BAFFR bicistronic chimeric antigen receptor T cells with potent antitumor activity against B-cell lineage neoplasms.
    Br J Haematol. 2024;205:1361-1373.
    >> Share

  105. BARONE A, Chiappella A, Casadei B, Bramanti S, et al
    Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: A report from the Italian CART-SIE study.
    Br J Haematol. 2024;205:1356-1360.
    >> Share

    September 2024
  106. LIU J, Gao F, Zhang T, Wang J, et al
    Time to lymphoma treatment within 24 months in 'watch and wait' follicular lymphoma is associated with inferior outcomes: A multicentre analysis.
    Br J Haematol. 2024 Sep 26. doi: 10.1111/bjh.19770.
    >> Share

  107. STRATI P, Champion R, Coleman M, Smith SM, et al
    Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study.
    Br J Haematol. 2024 Sep 22. doi: 10.1111/bjh.19787.
    >> Share

  108. MUNSHI M, Liu X, Kofides A, Tsakmaklis N, et al
    ERK1/2 pro-survival signalling is suppressed by pirtobrutinib in ibrutinib-resistant MYD88-mutated lymphoma cells.
    Br J Haematol. 2024 Sep 18. doi: 10.1111/bjh.19756.
    >> Share

  109. KURUVILLA J, Rushton C, Villa D, Aslam M, et al
    A randomized trial of ibrutinib and R-GDP prior to stem cell transplant in relapsed diffuse large B-cell lymphoma.
    Br J Haematol. 2024 Sep 12. doi: 10.1111/bjh.19764.
    >> Share

  110. NARESH KN
    Understanding splenic B-cell lymphoma/leukaemia with prominent nucleoli: Diagnosis, underpinnings for disease classification and future directions.
    Br J Haematol. 2024 Sep 10. doi: 10.1111/bjh.19754.
    >> Share

  111. FORSGREN E, Ekberg S, Smedby KE, Nylund P, et al
    Evaluation of coverage, generalisability and validity of the U-CAN lymphoma biobank in Sweden: A comparison with nationwide registers.
    Br J Haematol. 2024 Sep 3. doi: 10.1111/bjh.19732.
    >> Share

  112. SHOUVAL R, Goldman A, Flynn JR, El-Moghraby A, et al
    Atrial arrhythmias following CAR-chimeric antigen receptor T-cell therapy: Incidence, risk factors and biomarker profile.
    Br J Haematol. 2024;205:978-989.
    >> Share

    August 2024
  113. PIGNOT PE, Bahri H, Malartre S, Morisset S, et al
    Impact of the total lesion glycolysis (TLG) in predicting response of follicular lymphoma to rituximab.
    Br J Haematol. 2024 Aug 27. doi: 10.1111/bjh.19724.
    >> Share

  114. KUMAR EA, Korfi K, Bewicke-Copley F, Close K, et al
    CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma.
    Br J Haematol. 2024 Aug 26. doi: 10.1111/bjh.19671.
    >> Share

  115. WILSON MR, Cwynarski K, Eyre TA, Smith J, et al
    Central nervous system prophylaxis in large B-cell lymphoma: A British Society for Haematology Good Practice Paper.
    Br J Haematol. 2024 Aug 11. doi: 10.1111/bjh.19686.
    >> Share

  116. HERSHENFELD SA, Tobin JWD, Shelton V, Calvente L, et al
    Single gene mutations and prognosis in limited-stage follicular lymphoma treated with radiation therapy.
    Br J Haematol. 2024 Aug 7. doi: 10.1111/bjh.19698.
    >> Share

  117. YI JH, Kim SJ, Yang DH, Do YR, et al
    Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma.
    Br J Haematol. 2024 Aug 5. doi: 10.1111/bjh.19659.
    >> Share

  118. AARNIVALA H, Giertz M, Michelsen SW, Bjorklund C, et al
    Radiological follow-up of osteonecrosis lesions in children and adolescents with Hodgkin lymphoma.
    Br J Haematol. 2024 Aug 3. doi: 10.1111/bjh.19687.
    >> Share

  119. CORAZZELLI G, Cuccaro A, Morelli E, Arcamone M, et al
    Long-term efficacy and safety of dose-dense and dose-intense ABVD without consolidation radiotherapy in patients with advanced Hodgkin lymphoma: A 15-year follow-up of the ABVD(DD-DI) phase II study.
    Br J Haematol. 2024 Aug 1. doi: 10.1111/bjh.19646.
    >> Share

  120. MUHSEN IN, Heslop HE
    Time to optimize vaccination strategies in blood cancer patients.
    Br J Haematol. 2024;205:406-408.
    >> Share

    July 2024
  121. SPRIANO F, Tarantelli C, Cascione L, Gaudio E, et al
    Targeting CD25+ lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents.
    Br J Haematol. 2024 Jul 30. doi: 10.1111/bjh.19658.
    >> Share

  122. BALZAROTTI M, Bagnoli F
    Rolling the DICEP on lymphoma salvage treatments? Choose wisely.
    Br J Haematol. 2024 Jul 27. doi: 10.1111/bjh.19655.
    >> Share

  123. KAMIJO K, Shimomura Y, Kim SW, Ohigashi H, et al
    Reduced-intensity conditioning with fludarabine/busulfan versus fludarabine/low-dose melphalan in patients with non-Hodgkin lymphoma undergoing allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2024 Jul 24. doi: 10.1111/bjh.19651.
    >> Share

  124. GALLAMINI A, Filippi A, Camus V, Vassilakopoulos TP, et al
    Toward a paradigm shift in prognostication and treatment of early-stage Hodgkin lymphoma.
    Br J Haematol. 2024 Jul 22. doi: 10.1111/bjh.19657.
    >> Share

  125. PINTO A, Caltagirone M, Battista M, Gazzoli GC, et al
    Exposure to obinutuzumab does not affect outcomes of SARS-CoV-2 infection in vaccinated patients with newly diagnosed advanced-stage follicular lymphoma.
    Br J Haematol. 2024 Jul 22. doi: 10.1111/bjh.19661.
    >> Share

  126. CARLO-STELLA C
    Relapse after glofitamab, a novel unmet medical need with high rates of CD20 loss.
    Br J Haematol. 2024;205:17-19.
    >> Share

  127. GRIGG S, Minson A, Prins E, Dickinson MJ, et al
    Relapse after glofitamab has a poor prognosis and rates of CD20 loss are high.
    Br J Haematol. 2024;205:122-126.
    >> Share

  128. CIVALLERO M, Schroers-Martin JG, Horwitz S, Manni M, et al
    Long-term outcome of peripheral T-cell lymphomas: Ten-year follow-up of the International Prospective T-cell Project.
    Br J Haematol. 2024;205:166-174.
    >> Share

    June 2024
  129. CAVALLO F, Clerico M, Lucchini E, Castiglione A, et al
    Carfilzomib, lenalidomide, dexamethasone (KRD) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi.
    Br J Haematol. 2024 Jun 28. doi: 10.1111/bjh.19617.
    >> Share

  130. PRIOR D, Schmitt AD, Louissaint A, Mata DA, et al
    Large B-cell lymphoma with mystery rearrangement: Applying Hi-C to the detection of clinically relevant structural abnormalities.
    Br J Haematol. 2024 Jun 25. doi: 10.1111/bjh.19611.
    >> Share

  131. LIM YJ, Ward V, Brown A, Phillips E, et al
    Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.
    Br J Haematol. 2024 Jun 13. doi: 10.1111/bjh.19562.
    >> Share

  132. ROSSETTI S, Juul SJ, Eriksson F, Warming PE, et al
    Long-term cause-specific mortality in adolescent and young adult Hodgkin lymphoma patients treated with contemporary regimens-A nationwide Danish cohort study.
    Br J Haematol. 2024 Jun 12. doi: 10.1111/bjh.19586.
    >> Share

  133. SCIARRA R, Merli M, Cristinelli C, Lucioni M, et al
    Molecular characterization of diffuse large B-cell lymphomas associated with hepatitis C virus infection.
    Br J Haematol. 2024;204:2242-2253.
    >> Share

    May 2024
  134. SHORTT J, Opat S
    Large cell lymphoma through a liquid lens.
    Br J Haematol. 2024 May 30. doi: 10.1111/bjh.19502.
    >> Share

  135. ALCOCEBA M, Stewart JP, Garcia-Alvarez M, Diaz LG, et al
    Liquid biopsy for molecular characterization of diffuse large B-cell lymphoma and early assessment of minimal residual disease.
    Br J Haematol. 2024 May 29. doi: 10.1111/bjh.19458.
    >> Share

  136. STEWART DA, Kuruvilla J, Lee D, Dudebout JJ, et al
    Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide,
    Br J Haematol. 2024 May 27. doi: 10.1111/bjh.19555.
    >> Share

  137. OTHMAN T, Baird JH, Pak S, Mei M, et al
    Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma.
    Br J Haematol. 2024 May 26. doi: 10.1111/bjh.19521.
    >> Share

  138. EPPERLA N, Hashmi H, Ahn KW, Allbee-Johnson M, et al
    Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: A CIBMTR analysis.
    Br J Haematol. 2024 May 26. doi: 10.1111/bjh.19569.
    >> Share

  139. RUPAKUMAR T, Sankar A, Vijayasekharan K, Varikkattu Rajendran P, et al
    Older age, CNS leukaemic involvement and induction tumour lysis increases the risk of methotrexate (MTX)-induced neurotoxicity in childhood acute lymphoblastic leukaemia/lymphoma: Experience from a tertiary care centre in South India.
    Br J Haematol. 2024 May 26. doi: 10.1111/bjh.19559.
    >> Share

  140. HOFER KD, Wolfensberger N, Bachofner A, Schneidawind C, et al
    B-cell maturation antigen-directed bispecific antibodies in plasmablastic lymphoma.
    Br J Haematol. 2024 May 23. doi: 10.1111/bjh.19571.
    >> Share

  141. COELHO J, Roush SM, Xu AM, Puranam K, et al
    HIV and prior exposure to antiretroviral therapy alter tumour composition and tumour: T-cell associations in diffuse large B-cell lymphoma.
    Br J Haematol. 2024 May 20. doi: 10.1111/bjh.19531.
    >> Share

  142. BROCKELMANN PJ
    Considerations for anti-PD1-based first-line treatment of Hodgkin lymphoma.
    Br J Haematol. 2024 May 16. doi: 10.1111/bjh.19534.
    >> Share

  143. KUCZMARSKI TM, Lynch RC
    Managing common toxicities associated with checkpoint inhibitor and chemotherapy combinations for untreated classic Hodgkin lymphoma.
    Br J Haematol. 2024 May 2. doi: 10.1111/bjh.19478.
    >> Share

  144. SOUMERAI JD, Diefenbach CS, Jagadeesh D, Asch A, et al
    Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas.
    Br J Haematol. 2024;204:1762-1770.
    >> Share

  145. BRILLEMBOURG H, Martinez-Cibrian N, Bachiller M, Alserawan L, et al
    The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies.
    Br J Haematol. 2024;204:1649-1659.
    >> Share

  146. FARDELLA E, Zanirato G, Magni M, Caldarelli N, et al
    Prognostic impact of pretreatment cell-free DNA concentration in newly diagnosed peripheral T-cell lymphomas.
    Br J Haematol. 2024;204:1752-1756.
    >> Share

    April 2024
  147. VANDTVED JH, Ovlisen AK, Baech J, Weinrich UM, et al
    Pulmonary diseases in patients with classical Hodgkin lymphoma relative to a matched background population: A Danish national cohort study.
    Br J Haematol. 2024 Apr 29. doi: 10.1111/bjh.19475.
    >> Share

  148. HUO W, Gao L, Song K, Huang J, et al
    Allogeneic haematopoietic stem cell transplantation for adult T-lymphoblastic lymphoma: A real-world multicentre analysis in China.
    Br J Haematol. 2024 Apr 25. doi: 10.1111/bjh.19481.
    >> Share

  149. LEWIS CS, Joy G, Jensen P, Barraclough A, et al
    Primary gastric diffuse large B-cell lymphoma: A multicentre retrospective study.
    Br J Haematol. 2024 Apr 17. doi: 10.1111/bjh.19470.
    >> Share

  150. CAO XY, Zhang JP, Lu Y, Zhao YL, et al
    A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T-cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen r
    Br J Haematol. 2024 Apr 13. doi: 10.1111/bjh.19445.
    >> Share

  151. GANAPATHI KA, Nicolae A, Egan C, Geng H, et al
    Peripheral T-cell lymphomas expressing CD30 and CD15 expand the spectrum of anaplastic large cell lymphoma, ALK-negative.
    Br J Haematol. 2024 Apr 12. doi: 10.1111/bjh.19442.
    >> Share

  152. KUHNL A, Roddie C, Kirkwood AA, Chaganti S, et al
    Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK.
    Br J Haematol. 2024 Apr 9. doi: 10.1111/bjh.19453.
    >> Share

  153. MARTYNCHYK A, Hawkes EA
    Learnings from phosphatidylinositol 3-kinase inhibitors in lymphoma-Moving to a model where less can be more.
    Br J Haematol. 2024 Apr 6. doi: 10.1111/bjh.19456.
    >> Share

  154. ATALLAH-YUNES SA, Habermann TM, Khurana A
    Targeted therapy in Burkitt lymphoma: Small molecule inhibitors under investigation.
    Br J Haematol. 2024 Apr 5. doi: 10.1111/bjh.19425.
    >> Share

  155. MILROD CJ, Kim KW, Raker C, Ollila TA, et al
    Progression-free survival is a weakly predictive surrogate end-point for overall survival in follicular lymphoma: A systematic review and meta-analysis.
    Br J Haematol. 2024 Apr 4. doi: 10.1111/bjh.19449.
    >> Share

  156. BOMMANNAN K, Arumugam JR, Radhakrishnan V, Sundersingh S, et al
    Relevance of CD20 antigen expression among paediatric patients with B-lineage acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:1367-1374.
    >> Share

  157. MOULIN C, Beaupain B, Suarez F, Bertrand Y, et al
    CXCR4 WHIM syndrome is a cancer predisposition condition for virus-induced malignancies.
    Br J Haematol. 2024;204:1383-1392.
    >> Share

    March 2024
  158. MERLI M, Costantini A, Tafuri S, Bavaro DF, et al
    Management of vaccinations in patients with non-Hodgkin lymphoma.
    Br J Haematol. 2024 Mar 26. doi: 10.1111/bjh.19422.
    >> Share

  159. MANOS K, Churilov L, Grigg A, Di Ciaccio P, et al
    Infection risk and antimicrobial prophylaxis in bendamustine-treated patients with indolent non-Hodgkin lymphoma: An Australasian Lymphoma Alliance study.
    Br J Haematol. 2024 Mar 14. doi: 10.1111/bjh.19407.
    >> Share

  160. BAPTISTA P, Aguiar E, Fonseca E, Pinto R, et al
    Intravascular large B-cell lymphoma presenting with haemophagocytic syndrome.
    Br J Haematol. 2024 Mar 12. doi: 10.1111/bjh.19350.
    >> Share

  161. LI X, Gao F, Meng X, Zhang X, et al
    Epidemiological features and prognosis for primary gastrointestinal follicular lymphoma.
    Br J Haematol. 2024 Mar 6. doi: 10.1111/bjh.19393.
    >> Share

  162. NGUYEN PC, Nguyen T, Wilson C, Tiong IS, et al
    Evaluation of T-cell clonality by anti-TRBC1 antibody-based flow cytometry and correlation with T-cell receptor sequencing.
    Br J Haematol. 2024;204:910-920.
    >> Share

  163. AL-MASHHADI AL, Jakobsen LH, Brown P, Gang AO, et al
    Real-world outcomes following third or subsequent lines of therapy: A Danish population-based study on 189 patients with relapsed/refractory large B-cell lymphomas.
    Br J Haematol. 2024;204:839-848.
    >> Share

    February 2024
  164. BISHTON MJ, Crooks CJ, Card TR, West J, et al
    Ethnicity and socio-economic status affects the incidence and survival of hepatosplenic T-cell lymphoma.
    Br J Haematol. 2024 Feb 29. doi: 10.1111/bjh.19371.
    >> Share

  165. YE P, Cheng Y, Lian J, Tong H, et al
    Etoposide combined with cytarabine and pegfilgrastim for poorly mobilizing patients with multiple myeloma and lymphoma: A prospective multicentre study.
    Br J Haematol. 2024 Feb 23. doi: 10.1111/bjh.19367.
    >> Share

  166. STEPANISHYNA Y, Manni M, Civallero M, Shokun N, et al
    Outcome of malignant lymphoma in Ukraine. Analysis of 563 cases registered in the Ukrainian Lymphoma Registry in 2019-2021.
    Br J Haematol. 2024 Feb 23. doi: 10.1111/bjh.19352.
    >> Share

  167. FLORA DR, Parsons SK, Liu N, Yu KS, et al
    Patient preferences in the treatment of stage III/IV classic Hodgkin lymphoma: Results from the CONNECT cross-sectional survey.
    Br J Haematol. 2024 Feb 7. doi: 10.1111/bjh.19307.
    >> Share

  168. VOGELSBERG A, Harland L, Borgmann V, Otto F, et al
    Clonal haematopoiesis: A common progenitor for cytotoxic peripheral T-cell lymphoma and angioimmunoblastic T-cell lymphoma.
    Br J Haematol. 2024 Feb 7. doi: 10.1111/bjh.19335.
    >> Share

  169. BEDNARSKA K, Chowdhury R, Tobin JWD, Swain F, et al
    Epstein-Barr virus-associated lymphomas decoded.
    Br J Haematol. 2024;204:415-433.
    >> Share

  170. WANG Z, Fan Z, Wu Z, Xuan L, et al
    PASS-ALL study of paediatric-inspired versus adult chemotherapy regimens on survival of high-risk Philadelphia-negative B-cell acute lymphoblastic leukaemia with allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2024;204:628-637.
    >> Share

  171. KUMAR J, Ewalt MD, Zhang Y, Yao J, et al
    Novel identification of t(14;18)(q32;q21)/IGH::MALT1 in chronic lymphocytic leukaemia.
    Br J Haematol. 2024;204:561-565.
    >> Share

  172. PELLICCIA S, Rogges E, Cardoni A, Lopez G, et al
    The application of a multidisciplinary approach in the diagnosis of Castleman disease and Castleman-like lymphadenopathies: A 20-year retrospective analysis of clinical and pathological features.
    Br J Haematol. 2024;204:534-547.
    >> Share

    January 2024
  173. LUEDERSEN J, Stadt UZ, Richter J, Oschlies I, et al
    Variant ALK-fusion positive anaplastic large cell lymphoma (ALCL): A population-based paediatric study of the NHL-BFM study group.
    Br J Haematol. 2024 Jan 26. doi: 10.1111/bjh.19308.
    >> Share

  174. YANG P, Cai M, Cao Y, Fan S, et al
    Up-front autologous stem cell transplant in peripheral T-cell lymphoma patients achieving complete response after first-line treatment: A multicentre real-world analysis.
    Br J Haematol. 2024 Jan 25. doi: 10.1111/bjh.19317.
    >> Share

  175. ABEYAKOON C, Gregory GP
    New standards of care for treatment of diffuse large B-cell lymphoma.
    Br J Haematol. 2024 Jan 22. doi: 10.1111/bjh.19295.
    >> Share

  176. FOX CP, Chaganti S, McIlroy G, Barrington SF, et al
    The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline.
    Br J Haematol. 2024 Jan 21. doi: 10.1111/bjh.19273.
    >> Share

  177. LIAPIS K, Misidou C, Spanoudakis E, Kotsianidis I, et al
    Concurrent visceral leishmaniasis and diffuse large B-cell lymphoma of the bone marrow.
    Br J Haematol. 2024 Jan 7. doi: 10.1111/bjh.19283.
    >> Share

  178. WALEWSKA R, Eyre TA, Barrington S, Brady J, et al
    Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline.
    Br J Haematol. 2024;204:86-107.
    >> Share

  179. VISCO C
    Letting the mantle out of the bag.
    Br J Haematol. 2024;204:11-13.
    >> Share

  180. KHWAJA J, Vos JMI, Pluimers TE, Japzon N, et al
    Clinical and clonal characteristics of monoclonal immunoglobulin M-associated type I cryoglobulinaemia.
    Br J Haematol. 2024;204:177-185.
    >> Share

  181. DODERO A, Bramanti S, Di Trani M, Pennisi M, et al
    Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas.
    Br J Haematol. 2024;204:151-159.
    >> Share

    December 2023
  182. BAECH J, Husby S, Trab T, Kragholm K, et al
    Cardiovascular diseases after high-dose chemotherapy and autologous stem cell transplant for lymphoma: A Danish population-based study.
    Br J Haematol. 2023 Dec 28. doi: 10.1111/bjh.19272.
    >> Share

  183. MOTOMURA Y, Yoshifuji K, Tachibana T, Takase H, et al
    Clinical factors for central nervous system progression and survival in primary vitreoretinal lymphoma.
    Br J Haematol. 2023 Dec 22. doi: 10.1111/bjh.19266.
    >> Share

  184. TOTARO A, Calafiore AM, Sacra C, Magnano D, et al
    Huge right atrial mass in mantle cell lymphoma.
    Br J Haematol. 2023 Dec 21. doi: 10.1111/bjh.19258.
    >> Share

  185. JIN X, Zhou W, Jiang H, Chen Z, et al
    A case of a large number of Reed-Sternberg cells in pleural fluid following treatment of classical Hodgkin lymphoma.
    Br J Haematol. 2023 Dec 20. doi: 10.1111/bjh.19260.
    >> Share

  186. MASRONI MSB, Leong SM, Cheng H, Lim GS, et al
    miR-101-5p modulation of CD47 in diffuse large B-cell lymphoma: Implications for anti-CD47 immunotherapy and prognostication.
    Br J Haematol. 2023 Dec 12. doi: 10.1111/bjh.19264.
    >> Share

  187. FLOSPERGHER E, Marino F, Calimeri T, Cangi MG, et al
    Primary central nervous system marginal zone lymphoma.
    Br J Haematol. 2023 Dec 6. doi: 10.1111/bjh.19238.
    >> Share

  188. WU JF, Abid H, Szabo A, Abid MB, et al
    Impact of age on efficacy and safety of chimeric antigen receptor-T in B-cell acute lymphoblastic leukaemia-A systematic review and meta-analysis.
    Br J Haematol. 2023;203:e117-e120.
    >> Share

    November 2023
  189. SARTORI G, Tarantelli C, Spriano F, Gaudio E, et al
    The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.
    Br J Haematol. 2023 Nov 27. doi: 10.1111/bjh.19218.
    >> Share

  190. WATANABE T, Tobinai K, Wakabayashi M, Maruyama D, et al
    R-CHOP treatment for patients with advanced follicular lymphoma: Over 15-year follow-up of JCOG0203.
    Br J Haematol. 2023 Nov 23. doi: 10.1111/bjh.19213.
    >> Share

  191. HEINI AD, Bacher U, Pabst T
    Identification of novel targets for immunotherapies in subsets of patients with diffuse large B-cell lymphoma (DLBCL).
    Br J Haematol. 2023 Nov 14. doi: 10.1111/bjh.19195.
    >> Share

  192. CARACCIOLO D, Polera N, Belmonte B, Conforti F, et al
    UMG1/CD3epsilon-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma.
    Br J Haematol. 2023 Nov 14. doi: 10.1111/bjh.19183.
    >> Share

  193. PEDERSEN MA, Gormsen LC, Jakobsen LH, Eyre TA, et al
    The impact of CHOP versus bendamustine on bone mineral density in patients with indolent lymphoma enrolled in the GALLIUM study.
    Br J Haematol. 2023 Nov 13. doi: 10.1111/bjh.19194.
    >> Share

  194. GALLI E, Bellesi S, Pansini I, Di Cesare G, et al
    The CD4/CD8 ratio of infused CD19-CAR-T is a prognostic factor for efficacy and toxicity.
    Br J Haematol. 2023;203:564-570.
    >> Share

    October 2023
  195. MARTINEZ-CIBRIAN N, Ortiz-Maldonado V, Espanol-Rego M, Blazquez A, et al
    The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
    Br J Haematol. 2023 Oct 31. doi: 10.1111/bjh.19170.
    >> Share

  196. STUVER R, Noy A, Vardhana SA, Zelenetz AD, et al
    Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma.
    Br J Haematol. 2023 Oct 31. doi: 10.1111/bjh.19178.
    >> Share

  197. MINSON A, Hamad N, Di Ciaccio P, Talaulikar D, et al
    Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom.
    Br J Haematol. 2023 Oct 30. doi: 10.1111/bjh.19179.
    >> Share

  198. GONG IY, Prica A, Ante Z, Calzavara A, et al
    Indolent lymphoma care delivery and outcomes during the COVID-19 pandemic in Ontario, Canada.
    Br J Haematol. 2023 Oct 27. doi: 10.1111/bjh.19166.
    >> Share

  199. RAMSOWER CA, Rosenthal A, Robetorye RS, Mwangi R, et al
    Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab.
    Br J Haematol. 2023 Oct 25. doi: 10.1111/bjh.19153.
    >> Share

  200. EYRE TA, Bishton MJ, McCulloch R, O'Reilly M, et al
    Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline.
    Br J Haematol. 2023 Oct 25. doi: 10.1111/bjh.19131.
    >> Share

  201. CALABRETTA E, di Trani M, Corrado F, Sollini M, et al
    Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphoma.
    Br J Haematol. 2023 Oct 18. doi: 10.1111/bjh.19162.
    >> Share

  202. BOYLE S, Roddie C, O'Reilly M, Menne T, et al
    Improved outcomes of large B-cell lymphoma patients treated with CD19 CAR T in the UK over time.
    Br J Haematol. 2023 Oct 17. doi: 10.1111/bjh.19157.
    >> Share

  203. KYVSGAARD ER, Riley C, Clausen MR, Harslof M, et al
    Low mortality from COVID-19 infection in patients with B-cell lymphoma after bispecific CD20xCD3 therapy.
    Br J Haematol. 2023 Oct 13. doi: 10.1111/bjh.19156.
    >> Share

  204. MAMLOUK O, Strati P, Feng L, Sun R, et al
    Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function.
    Br J Haematol. 2023 Oct 11. doi: 10.1111/bjh.19152.
    >> Share

  205. CONTARINI G, Carraro E, Lovisa F, Martire G, et al
    Quantitative assessment of minimal residual disease for monitoring of paediatric patients with relapsed/refractory anaplastic large-cell lymphoma treated with brentuximab vedotin: A case series.
    Br J Haematol. 2023 Oct 11. doi: 10.1111/bjh.19151.
    >> Share

  206. LIU H, He Z, Gui R, Guo J, et al
    Stratified management based on surface antibody for the prevention of hepatitis B virus reactivation in lymphoma patients.
    Br J Haematol. 2023 Oct 6. doi: 10.1111/bjh.19140.
    >> Share

  207. GAO J, Dahiya S, Patel SA
    Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas.
    Br J Haematol. 2023;203:161-168.
    >> Share

    September 2023
  208. LEWIS KL, Cheah CY
    Chimeric antigen receptor T-cell therapy for mantle cell lymphoma with central nervous system involvement: Progress, but not perfect.
    Br J Haematol. 2023 Sep 24. doi: 10.1111/bjh.19095.
    >> Share

  209. HAYASHI K, Koyama D, Sato Y, Fukatsu M, et al
    Lymphoplasmacytic lymphoma presenting cold agglutinin syndrome: Clonal expansion of KMT2D and IGHV4-34 mutations after COVID-19.
    Br J Haematol. 2023 Sep 11. doi: 10.1111/bjh.19106.
    >> Share

  210. XIONG J, Zhao WL
    A novel SLC1A1-RIC1 fusion sensitive to asparaginase-based therapy in natural killer/T-cell lymphoma.
    Br J Haematol. 2023 Sep 1. doi: 10.1111/bjh.19066.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016